{"filing":{"accession_number":"0001619856-26-000043","cik":"0001619856","ticker":"CRBU","company_name":"Caribou Biosciences, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"crbu-20260611.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000043/crbu-20260611.htm"},"events":[{"id":5488,"run_id":4810,"accession_number":"0001619856-26-000043","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Caribou Biosciences announced clinical trial data from two ongoing phase 1 trials: ANTLER for vispa-cel in relapsed/refractory B-cell non-Hodgkin lymphoma (82% ORR, 67% CR) and CaMMouflage for CB-011 in relapsed/refractory multiple myeloma (92% ORR, 83% ≥CR). The data, presented at the EHA 2026 Annual Meeting, demonstrates progress toward planned phase 3 trials and is material to investors assessing the company's pipeline advancement and regulatory pathway.","company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6099,"accession_number":"0001619856-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical trial data from two ongoing phase 1 trials (ANTLER for vispa-cel in r/r B-NHL and CaMMouflage for CB-011 in r/r MM) with presentations scheduled at the EHA 2026 Annual Meeting. While this is material clinical progress for a biopharmaceutical company, it does not fit neatly into the standard taxonomy categories—it is neither an earnings release (financial results), nor a specific corporate event like M\u0026A, litigation, or executive changes. Clinical trial data announcements are typically material to investors in biotech companies assessing pipeline progress and regulatory pathway advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:04:10.775867+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6100,"accession_number":"0001619856-26-000043","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces long-term follow-up clinical trial data from two ongoing phase 1 trials (ANTLER for vispa-cel in r/r B-NHL and CaMMouflage for CB-011 in r/r MM), including efficacy endpoints (82% ORR and 67% CR for vispa-cel; 92% ORR and 83% ≥CR for CB-011) and safety profiles. While clinical trial results are material to a biopharmaceutical company's prospects, this does not fit the \"earnings_release\" category (which typically refers to financial results) nor any other specific event type. The data supports advancement toward a planned phase 3 trial (ANTLER-3) and demonstrates progress in the company's pipeline, making it material to investors assessing the registrant's development stage and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:04:10.775867+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6099,"accession_number":"0001619856-26-000043","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces clinical trial data from two ongoing phase 1 trials (ANTLER for vispa-cel in r/r B-NHL and CaMMouflage for CB-011 in r/r MM) with presentations scheduled at the EHA 2026 Annual Meeting. While this is material clinical progress for a biopharmaceutical company, it does not fit neatly into the standard taxonomy categories—it is neither an earnings release (financial results), nor a specific corporate event like M\u0026A, litigation, or executive changes. Clinical trial data announcements are typically material to investors in biotech companies assessing pipeline progress and regulatory pathway advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:04:10.775867+00:00","company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","filing_date":"2026-06-11"},{"id":6100,"accession_number":"0001619856-26-000043","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces long-term follow-up clinical trial data from two ongoing phase 1 trials (ANTLER for vispa-cel in r/r B-NHL and CaMMouflage for CB-011 in r/r MM), including efficacy endpoints (82% ORR and 67% CR for vispa-cel; 92% ORR and 83% ≥CR for CB-011) and safety profiles. While clinical trial results are material to a biopharmaceutical company's prospects, this does not fit the \"earnings_release\" category (which typically refers to financial results) nor any other specific event type. The data supports advancement toward a planned phase 3 trial (ANTLER-3) and demonstrates progress in the company's pipeline, making it material to investors assessing the registrant's development stage and therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T12:04:10.775867+00:00","company_name":"Caribou Biosciences, Inc.","ticker":"CRBU","filing_date":"2026-06-11"}]}